Antibodi Monoklonal untuk Kanker Endometrium – Artikel Terkini!

Oleh :

dr. Cipta Pramana SpOGK

Terapi target dengan antibodi monoklonal telah dilaporkan bermanfaat untuk penanganan kanker endometrium. Kanker endometrium merupakan neoplasia organ genitalia wanita yang paling sering timbul, terutama pada wanita pascamenopause, dengan usia rerata saat diagnosis adalah 60 tahun. Pada tahun 2020, dilaporkan terdapat 60.000 kasus baru kanker endometrium di Amerika Serikat dan lebih dari 12.000 wanita meninggal karena kanker ini.[1,2]

Banyak faktor mempengaruhi risiko terkena kanker endometrium, termasuk obesitas, konsumsi estrogen setelah menopause, riwayat kontrasepsi hormonal, sindrom ovarium polikistik (PCOS), serta riwayat keluarga dengan kanker endometrium atau kolorektal. Terapi utama kanker endometrium adalah dengan operasi. Terapi tambahan biasanya mencakup radioterapi pelvis, brakiterapi vagina, kemoterapi, dan kombinasi kemoterapi dan radioterapi.[3-5]

Studi tentang karakteristik molekuler kanker endometrium telah mengarah pada identifikasi perubahan molekuler yang dapat ditargetkan. Atas dasar temuan ini, terapi target, terutama antibodi monoklonal, diduga dapat bermanfaat dalam pengobatan kanker endometrium.[6,7]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Paleari L, Pesce S, Rutigliani M, Greppi M, Obino V, Gorlero F, et al. New insights into endometrial cancer. Cancers (Basel). 2021;13(7).
2. American Cancer Society. Key Statistics for Endometrial Cancer. 2024. https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.html
3. American Cancer Society. Endometrial Cancer Risk Factors. 2019. https://www.cancer.org/cancer/types/endometrial-cancer/causes-risks-prevention/risk-factors.html
4. Ignatov A, Ortmann O. Endocrine risk factors of endometrial cancer: Polycystic ovary syndrome, oral contraceptives, infertility, tamoxifen. Cancers (Basel). 2020;12(7):1–10.
5. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, Glenn McCluggage W, Quinn D, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020;15(4):1–21.
6. Van Den Heerik ASVM, Horeweg N, De Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: Radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021;31(4):594–604.
7. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145–58.
8. Hussain HU, Burney MH, Rehan ST, Hasan MM. Dostarlimab: A breakthrough in the field of oncology. Ann Med Surg (Lond). 2022 Jul 5;80:104046. doi: 10.1016/j.amsu.2022.104046..
9. Di Donato V, Giannini A, Bogani G. Recent Advances in Endometrial Cancer Management. J Clin Med. 2023;12(6):10–1.
10. Bogani G, Mariani A, Paolini B, Ditto A, Raspagliesi F. Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. Gynecol Oncol. 2019;153(3):670–5. https://doi.org/10.1016/j.ygyno.2019.02.027
11. Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, et al. Monoclonal antibodies in gynecological cancer: A critical point of view. Clin Dev Immunol. 2011;2011(Table 1).
12. Stenger M. Dostarlimab-gxly With Chemotherapy for Endometrial Cancer. ASCO Post. 2023. https://ascopost.com/issues/september-10-2023/dostarlimab-gxly-with-chemotherapy-for-endometrial-cancer/
13. Rubio-Pérez J, Hernández R, Hernández T, Doger B, Casado V, Moreno V. Dostarlimab for the treatment of endometrium cancer and other solid tumors. Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.
14. Andres Redondo AG. Dostarlimab for the treatment of advanced endometrial cancer. Expert Rev Clin Pharmacol. 2022;15(1).